NeuroPace Provides Update on Tariff Status

Core Viewpoint - NeuroPace, Inc. expects minimal impact from U.S. tariffs on its operations and financial results, maintaining its gross margin guidance for fiscal year 2025 [1][2]. Group 1: Financial Performance - The company will report its first quarter 2025 financial results on May 13, 2025, with a conference call scheduled for the same day [3]. - NeuroPace anticipates no material impact on gross margin for its DIXI Medical SEEG products, reiterating its gross margin guidance for 2025 [2]. Group 2: Business Operations - NeuroPace manufactures and sells most of its devices in the U.S., with limited supply chain activities outside the country, which contributes to the expected minimal impact from tariffs [2]. - The company has announced the termination of its SEEG distribution agreement with DIXI Medical effective October 1, 2025, followed by a six-month wind-down period [2]. Group 3: Company Overview - NeuroPace is focused on transforming the lives of people with epilepsy through its RNS System, which is the first commercially available brain-responsive platform for personalized treatment [4].